Progyny (PGNY) Stock Price, News & Analysis

Company Overview

Progyny, Inc. (NASDAQ: PGNY) is a fertility and family-building benefits company that helps employers provide reproductive health services to their employees. Its platform is designed to support individuals and families navigating fertility treatment, preservation, adoption, surrogacy and related family-building needs.

The company offers an integrated benefits solution that combines personalized care navigation with access to a network of fertility specialists and treatment providers. Progyny also provides pharmacy benefits through Progyny Rx, helping members obtain and manage medications commonly used in fertility treatments.

Progyny primarily serves employer-sponsored benefit programs in the United States. The company was founded in 2016 and became a publicly traded company in 2019. Its leadership includes Peter Anevski, who serves as chief executive officer.

Key Stats

• Today's Range: $28.03 to $28.95
• 50-Day Range: $24.79 to $28.03
• 52-Week Range: $16.10 to $33.06
• Volume: 1.23 million shs
• Average Volume: 1.39 million shs
• Market Capitalization: $2.19 billion
• P/E Ratio: 31.07
• Dividend Yield: N/A
• Price Target: $34.36
• Consensus Rating: Moderate Buy

Progyny Stock Analysis - MarketRank™

Progyny scored higher than 82% of companies evaluated by MarketBeat, and ranked 80th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Progyny has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 1 strong buy rating, 9 buy ratings, 3 hold ratings, and no sell ratings.

Upside Potential

Progyny has a consensus price target of $34.36, representing about 20.2% upside from its current price of $28.58.

Amount of Analyst Coverage

Progyny has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 13.60%

Earnings Growth

Earnings for Progyny are expected to grow by 13.60% in the coming year, from $1.25 to $1.42 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Progyny is 31.07, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.75.

Price to Earnings Ratio vs. Sector

The P/E ratio of Progyny is 31.07, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.57.

Price to Earnings Growth Ratio

Progyny has a PEG Ratio of 1.85. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Progyny has a P/B Ratio of 4.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.36% of the float of Progyny has been sold short.

Short Interest Ratio / Days to Cover

Progyny has a short interest ratio ("days to cover") of 4.09.

Change versus previous month

Short interest in Progyny has recently increased by 8.14%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Progyny does not currently pay a dividend.

Dividend Growth

Progyny does not have a long track record of dividend growth.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 0.58

News Sentiment

Progyny has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Progyny this week, compared to 4 articles on an average week.

Search Interest

5 people have searched for PGNY on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Progyny to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Progyny insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $475,790.00 in company stock.

Percentage Held by Insiders

9.90% of the stock of Progyny is held by insiders.

Percentage Held by Institutions

94.93% of the stock of Progyny is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/20/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Providers & Services
• Sub-Industry: Healthcare Services
• Current Symbol: NASDAQ:PGNY
• CIK: 1551306
• Web: www.progyny.com
• Phone: 212-888-3124
• Fax: N/A
• Employees: 856
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Progyny: $34.36
• High Price Target: $40.00
• Low Price Target: $30.00
• Potential Upside/Downside: +20.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.85
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.92
• Trailing P/E Ratio: 31.07
• Forward P/E Ratio: 22.86
• P/E Growth: 1.85
• Net Income: $58.52 million
• Net Margins: 6.00%
• Pretax Margin: 9.14%
• Return on Equity: 15.98%
• Return on Assets: 10.65%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.14
• Quick Ratio: 2.14

Sales & Book Value

• Annual Sales: $1.29 billion
• Price / Sales: 1.70
• Cash Flow: $0.78 per share
• Price / Cash Flow: 36.49
• Book Value: $5.99 per share
• Price / Book: 4.77

Miscellaneous

• Outstanding Shares: 76,730,000
• Free Float: 69,131,000
• Market Cap: $2.19 billion
• Optionable: Optionable
• Beta: 1.02